MENU
+Compare
DSRLF
Stock ticker: OTC
AS OF
Jun 20 closing price
Price
$107.68
Change
-$0.98 (-0.90%)
Capitalization
5.99B

DSRLF stock forecast, quote, news & analysis

DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue... Show more

DSRLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for DSRLF with price predictions
Jun 27, 2025

DSRLF's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for DSRLF turned positive on June 02, 2025. Looking at past instances where DSRLF's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

DSRLF moved above its 50-day moving average on June 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for DSRLF crossed bullishly above the 50-day moving average on June 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DSRLF moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 27, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DSRLF as a result. In of 46 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Aroon Indicator for DSRLF entered a downward trend on June 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.101) is normal, around the industry mean (24.463). P/E Ratio (27.322) is within average values for comparable stocks, (77.706). DSRLF's Projected Growth (PEG Ratio) (179.924) is very high in comparison to the industry average of (5.667). Dividend Yield (0.012) settles around the average of (0.018) among similar stocks. P/S Ratio (3.702) is also within normal values, averaging (43.062).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DSRLF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DSRLF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

DSRLF paid dividends on May 26, 2021

Diasorin S.R.L. DSRLF Stock Dividends
А dividend of $1.00 per share was paid with a record date of May 26, 2021, and an ex-dividend date of May 24, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 8.65B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -0%. SERA experienced the highest price growth at 118%, while LUCY experienced the biggest fall at -41%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 100% and the average quarterly volume growth was 249%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 71
Price Growth Rating: 61
SMR Rating: 84
Profit Risk Rating: 90
Seasonality Score: 19 (-100 ... +100)
View a ticker or compare two or three
DSRLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
Via Crescentino Snc
Phone
+39 1614871
Employees
3386
Web
https://www.diasoringroup.com